Appointment of Joint Broker

Appointment of Joint Broker

Manchester, UK – 5 January 2018 - SkinBioTherapeutics plc (AIM: SBTX,  the “Company”), a life science company focused on skin health, announces the appointment of Northland Capital Partners to act as the Company's Joint Corporate Broker, alongside Turner Pope Investments, with immediate effect.

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

5th January, 2018
investors logo